It has been another strong start to the year for Seneca’s EIS funds, with no sign of a slowdown in private deal opportunities, alongside a marked increase in AIM company activity.
For the 4 months to the end of April 2024, Seneca made £670k of EIS investment (as a part of a total of £1.2m of growth capital funding when combined with the Seneca Growth Capital VCT). This investment was made into 3 AIM-listed businesses which together raised a total of £18m in what is a tough market, which we think is indicative of the quality of the assets.
These investments were:
- Verici Dx Plc, a developer of advanced clinical diagnostics for organ transplant, raised £6.5m to expedite growth following the announcement of a commercialisation agreement with Thermo Fisher for one of its products. This fundraise was supported very well, and in fact was oversubscribed, by shareholders and the ‘market’ more widely.
- OptiBiotix Health Plc, a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes, and skincare, raised c.£1.5m. This is a business well known to Seneca, with a CEO with a track record of delivering value for shareholders.
- Oxford Biodynamics Plc, a biotechnology company developing precision medicine tests, secured a total of £10m further funding to support the company as commercialisation of the two lead assets ramps up.
We expect to continue this momentum through the second quarter of the year and beyond. There is a good pipeline of both public and private opportunities currently under review by the team. We persist in our preference of well-funded businesses, with demonstrable traction, which can illustrate a good route to value creation and exit.
Undoubtedly the wider fundraise landscape remains a challenge for many, but this presents fertile investment ground for the growth capital space, and we remain encouraged by the quality of businesses seeking funding at this time.
Victoria Edwards
Investment Manager
8th May 2024
EIS investment is not for everyone. You can lose some or all of the money you invest. This article should not be taken as a recommendation to buy or sell shares in any of the companies named therein. Past performance is not a guide to future returns.